GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarey Drugs & Pharmaceuticals Ltd (BOM:524412) » Definitions » Piotroski F-Score

Aarey Drugs & Pharmaceuticals (BOM:524412) Piotroski F-Score : 1 (As of May. 17, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Aarey Drugs & Pharmaceuticals Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aarey Drugs & Pharmaceuticals has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Aarey Drugs & Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

BOM:524412' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 7
Current: 1

During the past 13 years, the highest Piotroski F-Score of Aarey Drugs & Pharmaceuticals was 7. The lowest was 1. And the median was 5.


Aarey Drugs & Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Aarey Drugs & Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarey Drugs & Pharmaceuticals Piotroski F-Score Chart

Aarey Drugs & Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 4.00 5.00 1.00

Aarey Drugs & Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.00 - - -

Competitive Comparison of Aarey Drugs & Pharmaceuticals's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Aarey Drugs & Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarey Drugs & Pharmaceuticals's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarey Drugs & Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Aarey Drugs & Pharmaceuticals's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Net Income was ₹38 Mil.
Cash Flow from Operations was ₹-13 Mil.
Revenue was ₹4,128 Mil.
Gross Profit was ₹90 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was (2451.688 + 2913.245) / 2 = ₹2682.4665 Mil.
Total Assets at the begining of this year (Mar22) was ₹2,452 Mil.
Long-Term Debt & Capital Lease Obligation was ₹44 Mil.
Total Current Assets was ₹2,706 Mil.
Total Current Liabilities was ₹1,681 Mil.
Net Income was ₹66 Mil.

Revenue was ₹4,916 Mil.
Gross Profit was ₹196 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was (2330.357 + 2451.688) / 2 = ₹2391.0225 Mil.
Total Assets at the begining of last year (Mar21) was ₹2,330 Mil.
Long-Term Debt & Capital Lease Obligation was ₹33 Mil.
Total Current Assets was ₹2,188 Mil.
Total Current Liabilities was ₹1,267 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aarey Drugs & Pharmaceuticals's current Net Income (TTM) was 38. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aarey Drugs & Pharmaceuticals's current Cash Flow from Operations (TTM) was -13. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar22)
=37.711/2451.688
=0.01538165

ROA (Last Year)=Net Income/Total Assets (Mar21)
=65.548/2330.357
=0.02812788

Aarey Drugs & Pharmaceuticals's return on assets of this year was 0.01538165. Aarey Drugs & Pharmaceuticals's return on assets of last year was 0.02812788. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Aarey Drugs & Pharmaceuticals's current Net Income (TTM) was 38. Aarey Drugs & Pharmaceuticals's current Cash Flow from Operations (TTM) was -13. ==> -13 <= 38 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=43.606/2682.4665
=0.01625593

Gearing (Last Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=33.4/2391.0225
=0.01396892

Aarey Drugs & Pharmaceuticals's gearing of this year was 0.01625593. Aarey Drugs & Pharmaceuticals's gearing of last year was 0.01396892. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=2706.058/1681.408
=1.60939998

Current Ratio (Last Year: Mar22)=Total Current Assets/Total Current Liabilities
=2188.169/1267.362
=1.72655405

Aarey Drugs & Pharmaceuticals's current ratio of this year was 1.60939998. Aarey Drugs & Pharmaceuticals's current ratio of last year was 1.72655405. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Aarey Drugs & Pharmaceuticals's number of shares in issue this year was 25.385. Aarey Drugs & Pharmaceuticals's number of shares in issue last year was 24.075. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=90.091/4128.498
=0.02182174

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=195.548/4916.097
=0.03977708

Aarey Drugs & Pharmaceuticals's gross margin of this year was 0.02182174. Aarey Drugs & Pharmaceuticals's gross margin of last year was 0.03977708. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar22)
=4128.498/2451.688
=1.68394102

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar21)
=4916.097/2330.357
=2.10958965

Aarey Drugs & Pharmaceuticals's asset turnover of this year was 1.68394102. Aarey Drugs & Pharmaceuticals's asset turnover of last year was 2.10958965. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+0+0+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aarey Drugs & Pharmaceuticals has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Aarey Drugs & Pharmaceuticals  (BOM:524412) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Aarey Drugs & Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Aarey Drugs & Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarey Drugs & Pharmaceuticals (BOM:524412) Business Description

Traded in Other Exchanges
Address
340/348, Narshi Natha Street, 107, Sahakar Bhavan, Masjid, Mumbai, MH, IND, 400 009
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, BMD among others. The company principally carries its business operations in India.

Aarey Drugs & Pharmaceuticals (BOM:524412) Headlines

No Headlines